• Explore /
  • Poster
  • / A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.

A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.

Abstract Poster

Authors

Noah Hahn

Noah M. Hahn

Departments of Oncology and Urology, Johns Hopkins School of Medicine, Baltimore, MD

Noah M. Hahn , Sam Chang , Maxwell Meng , Neal D. Shore , Badrinath R. Konety , Gary D. Steinberg , Juergen Gschwend , Hiroyuki Nishiyama , Joan Palou , John A Taylor III, Alexandre Lambert , Li Zhu , Toshiki Maeda , Bradley Raybold , Bruce S. Fischer , Chandrika Jeyamohan , Dimitrios Zardavas , Fred Witjes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT03519256

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS5090)

DOI

10.1200/JCO.2020.38.15_suppl.TPS5090

Abstract #

TPS5090

Poster Bd #

159

Abstract Disclosures

Similar Posters

First Author: Noah M. Hahn

First Author: Kevin Joseph Harrington

First Author: Zongren Wang

First Author: Arndt Vogel